direct antithrombins

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

atrial fibrillation

dabigatran
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002     ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003     ximelagatranwarfarin standard doseRisk of bias suggesting
SPORTIF V, 2005       ximelagatranwarfarin standard doseLow risk of bias suggesting

thrombosis prevention

dabigatran
RE-NOVATE (150mg), 2007      NCTdabigatran 150mgenoxaparinhip surgeryLow risk of bias negative
RE-NOVATE (220mg), 2007      NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative
RE-NOVATE 2    NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative
RE-MODEL (150mg), 2007     dabigatran 150mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative
RE-MODEL (220mg), 2007   dabigatran 220mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative
RE-MOBILIZE (150mg), 2008     dabigatran 150mgenoxaparin (US regimen)knee surgeryLow risk of bias negative
RE-MOBILIZE (220mg), 2008     dabigatran 220mgenoxaparin (US regimen)knee surgeryLow risk of bias negative
ximelagatran
METHRO I, 2002   ximelagatranDalteparinnegative
METHRO II, 2002     ximelagatranDalteparinLow risk of bias suggesting
Phase II (Heit), 2001     ximelagatranEnoxaparinLow risk of bias negative
Platinum (Colwell), 2003   ximelagatranEnoxaparinLow risk of bias negative
METHRO III, 2002         ximelagatranEnoxaparinLow risk of bias negative
EXPRESS, 2003     ximelagatranEnoxaparinLow risk of bias suggesting